Is anyone following the Epogen issues - media attention - Amgen - guidelines - controversy with FDA warning being sent out to providers to stay within the designated numbers ... Wondering how many patients have hgb over 12.5? Epogen, for example, provides about 22% revenue for FMC but Davita is on the carpet with the government AGAIN for their Epogen usage. :( Ofcourse, bottom line is that the patient suffers. Woudl like to know nurses experiences in addressing these issues with their medical directors - i.e. hgb is high, continuing to give Epo (per Dr.)?